{"ticker": {"uuid": "cdb53169-f08e-4509-9fef-82424c1bca56", "symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "exchange": "GER", "country": "DE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOUFZqN204bl96Vzc1Z2g4Z2I1ZWVQQUZQQlVWNFBjVW9zQm1yUWZvZnNLSWpuVFFzdjZENDU0SU5tMVVZaWI2WEp4RnNsV3ktNDktNG9MZlRFRl9jY2pCOWJvYTBmRXM1dkZMVWQzQkRxZEt3OVVJSkxRTVMwUHU2Zlh2WUJqOTBwdFBMdHdWMA?oc=5", "source_name": "The Business Journals", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron gMG drug cemdisiran clears FDA, EMA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPekhQeHZBSEYwbFFCWS1oMHZKWXhla1JxR2lHSzVFWjdaMlhZRWVDcTM0blNHem5GQ29VZkk5ejFBN0tIMFRpYk5feXQ2V1kzelc2NkR2M1VfM2FYeUd6aWQ3RVZ4OENjUDRBM0dCRlNGRm1KX19IMHhHY3QxWGEzMGJNUUlaSDRQU243Y2tFSVZpMTdnczJPSkFCMDlVcUNtSTB2UTlhQmlmdlVZZzQ1SlhJaDR3SWJfQVQ1a2VscmY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Announces Key Outcomes from 202", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQOVg3TlBPR1dwSWxRNkZfemktY0h5dDFTOVVwVVRGNkktX2tmV2VCZ3dRWkItR013al9TT0p2QlAtMnJIUERzSEhJcE8xQUFsWjhhQzVrbGpuSlFLR3hGWGpTYlNBaHJwM0RPbDlodHMyVDFfU045STIxRHlISi13Umk2cVI3VWtsTjJpVWNaTGR5WGJ1NXA4dFp1eUpWOVUtaHVJQXNMTUNVQjl5LUtXMkg3d2NtajZVYWN5SEJabUpYME5qakNhMGpYRFY3blNzNWp4M1c4YUI4aWlCRkR3ZkRnd1JaaHhzYkk4ZzFaQTZWSlBoWVVhcnd3SjNBdDg?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Obesity and ultra-rare bone disease data from Regeneron at June conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQdGRmVFBYTDRXMlI5Q19wSDZrT24zSGVZUWpTNDVEaEZScGNBdFZKQno0TWtMS29Nb0pCb29haWlCay16R19DWTU2ZU5mSkg1eS1iQ3pKX01wV0E5UHpFdG5ZTTJmM3IzRzBxQmNtaTRwOHI4UEJSNGNudmdEemxzNFdaYVh0QU11VFZycmhDaHQ2RDhLSEJIemM4NzdxczNIZTJGYnFWQzNBR3JRaGNXQjZUNGk3dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOdFFtWjBqUUZtY1JKVHVJczNUV0VsaUNsckR3cXY3SnlDbWlidlkzZ1RwNmR2LVpMM1FvdjZra2tvNVptS3JobG0zN0VvaHludjYtaW9waFplcHNXY0pCRFlpZ1NERWZjMjQwZUVJSWIydWlPZDZ6cEM1RkVlUmR5TDRUdmxmWWVOV3BXUkNVSWVyT050b09aRHFWWUF3d3hwTnVfYjUtYU8wM19pel9qTXVrTmhXaE5GU2FQeHVveldOVTdC?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNX015eVNYZjFJWDZ0ajR2elNwVkZmRmR3Q0V6ckNxZGRGXy1yb3dBT0tOWTV2SkxDbktKeXRMdnZGT3Q0Vnpiald4ZmQzNjhSaFg1THBycTB2SUJPRkladUxlZkpOd2RVMFpkekpybGFqbVEtUVZZVTdPQUd4Q3ZXVkVFQVJkQlIyNlpobWZkSFBRVjBMdTBxUWZEMEF2dXFkVmR4UW5zdGpGX2R5T0NvaHdaYmJQZVlIMHQxQmdYOEhhNlNGZTZuY0xXOG9aMjhxMUhNYw?oc=5", "source_name": "Reuters", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Today's Analyst Rating Update for Regeneron Pharmaceuticals (REG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOVXdYVXhfZnEzTGdqdXZKNGREU0tyZW1pWmxUOHptRl92OHJ1blZUakhZZ2JQamJyenlHSUxFdTJjUThpcVBnUjhYV3EzQnRiTXNxQ0tsRDZ6SGtiTm16WUdSRTBlUENIcmt1Ym05UVBBR2NqcmRwQ3VQdlY1RkM3VmVnOExFV2xNMDBHbmF4OUQ0dzk0X3FWRUlCaUg0MlhONnU1QkgwU19UWXh0R0kxZGozZVNDRW5ialE?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdHhac3NzT2hjRTJ2VXZOOXhrQXhCR3lEd25wNm9OZXpOekRBTzlfdDBGXzQ1dDdpOUJCUDZKcG5MWUFlYzVDZVFmYVZmcnN3U3hJdVF6aXhneGx6S3hKaTB5ZkFVWjF1WjIxVUc0TTlraFZBLWd3dXVoZVc3V25xRGd4QXJhN08weDBxalN3R20xbWNsQVdzSjVwc0dnTExfdUQzRjkwYjZ4X25ldnhJ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron's immune disorder therapy improves daily functions in trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcXVZS0FBT3NheTNkS29hVm9MSVhqN0lPTVozSGRzcW02UXdqQkN2TUlCWHdmUEpPczQwcEc5d1Y1aU41dFg3eWhDLUpKV2lsLXhITDdLdDZGRGxERUdzeFpBNU1wMVlIVDROQnZ4ZFBxZ3lPMUxEbk44UHF6QmNHMHFJcFRoUHB0NFlBcEhpeEtMOVNuOXhZNzJIWDJ4dFR4bFFoVnlXRU4wZ0JmaFdTMEthdnlNWEczNEhmdUlFNFlCVEFwTzM2enNPZG0tc2t0QlU0?oc=5", "source_name": "Reuters", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxQRHVZZ2c5ZnFWc1c2Um9WTUxIQ05nS0dDUXZvZTE1TktOak5aNk9DSm5MMEFFdHNHS2V0S1ppbTROSk1RT2xfT2hfWnVjYnRoOTRKYmpaY3c2clBrUjNVaGYzNHI1dHNFczUyQ0swbHZLSm9GUHJvWUt6Ri04YnIzZEVFQVN1NGV3Q2w5SWtQTGFuMVRsS0VVRUJCczlQaFpKdnUtSWxJRzdMMTROTURXeExoNF9qYlhvcWtBZ25TS3oxeWRuRnFQbWhtbjd6ajBpUC1FQTdxTWZPVTA3TGQwSzhDcms4ZHdZeEpta2IzeFVmQ2N5bklpczdxZ3l1Tk1BUlE?oc=5", "source_name": "PR Newswire", "published_at": "2025-03-03T08:00:00+00:00", "published_display": "03 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOdU9vV21NTGw4SjN6YmdJS0l2d1pMbXRxdlJRc01ZUkRkaGQyWVQ1OVZpZlowTTNJM0Y5SHhHVXF0cHFJSEFjTW9EQlNiMHFCbUZURFNtcFVuZmtMa1MtcmhkaW5nOWVCQWVRS0F2bkt4c1ZHd2tROThBYloydHNMQjZqLUkzZF9ua0M5OElkelRFQVAwc18xNzNhUThxT3ZnRkoxa2pxUjBYaUFKeWtCcGRFZGY0bFBiSkU0a1NESFNNb2VSMkpTblNrQXVVbWpTemJBOC1KNnJMWmxuQUVjMjVMYWg4TFJscEo1U2VuMmtpM3RBSDNfMlJ1TGJlSHRqdExHbkI3cS1wRkZ2MFAyTTdydnVXVm9LWENCdHNB?oc=5", "source_name": "PR Newswire", "published_at": "2025-01-09T08:00:00+00:00", "published_display": "09 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOUFZqN204bl96Vzc1Z2g4Z2I1ZWVQQUZQQlVWNFBjVW9zQm1yUWZvZnNLSWpuVFFzdjZENDU0SU5tMVVZaWI2WEp4RnNsV3ktNDktNG9MZlRFRl9jY2pCOWJvYTBmRXM1dkZMVWQzQkRxZEt3OVVJSkxRTVMwUHU2Zlh2WUJqOTBwdFBMdHdWMA?oc=5", "source_name": "The Business Journals", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron gMG drug cemdisiran clears FDA, EMA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPekhQeHZBSEYwbFFCWS1oMHZKWXhla1JxR2lHSzVFWjdaMlhZRWVDcTM0blNHem5GQ29VZkk5ejFBN0tIMFRpYk5feXQ2V1kzelc2NkR2M1VfM2FYeUd6aWQ3RVZ4OENjUDRBM0dCRlNGRm1KX19IMHhHY3QxWGEzMGJNUUlaSDRQU243Y2tFSVZpMTdnczJPSkFCMDlVcUNtSTB2UTlhQmlmdlVZZzQ1SlhJaDR3SWJfQVQ1a2VscmY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Announces Key Outcomes from 202", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQOVg3TlBPR1dwSWxRNkZfemktY0h5dDFTOVVwVVRGNkktX2tmV2VCZ3dRWkItR013al9TT0p2QlAtMnJIUERzSEhJcE8xQUFsWjhhQzVrbGpuSlFLR3hGWGpTYlNBaHJwM0RPbDlodHMyVDFfU045STIxRHlISi13Umk2cVI3VWtsTjJpVWNaTGR5WGJ1NXA4dFp1eUpWOVUtaHVJQXNMTUNVQjl5LUtXMkg3d2NtajZVYWN5SEJabUpYME5qakNhMGpYRFY3blNzNWp4M1c4YUI4aWlCRkR3ZkRnd1JaaHhzYkk4ZzFaQTZWSlBoWVVhcnd3SjNBdDg?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Obesity and ultra-rare bone disease data from Regeneron at June conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQdGRmVFBYTDRXMlI5Q19wSDZrT24zSGVZUWpTNDVEaEZScGNBdFZKQno0TWtMS29Nb0pCb29haWlCay16R19DWTU2ZU5mSkg1eS1iQ3pKX01wV0E5UHpFdG5ZTTJmM3IzRzBxQmNtaTRwOHI4UEJSNGNudmdEemxzNFdaYVh0QU11VFZycmhDaHQ2RDhLSEJIemM4NzdxczNIZTJGYnFWQzNBR3JRaGNXQjZUNGk3dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOdFFtWjBqUUZtY1JKVHVJczNUV0VsaUNsckR3cXY3SnlDbWlidlkzZ1RwNmR2LVpMM1FvdjZra2tvNVptS3JobG0zN0VvaHludjYtaW9waFplcHNXY0pCRFlpZ1NERWZjMjQwZUVJSWIydWlPZDZ6cEM1RkVlUmR5TDRUdmxmWWVOV3BXUkNVSWVyT050b09aRHFWWUF3d3hwTnVfYjUtYU8wM19pel9qTXVrTmhXaE5GU2FQeHVveldOVTdC?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNX015eVNYZjFJWDZ0ajR2elNwVkZmRmR3Q0V6ckNxZGRGXy1yb3dBT0tOWTV2SkxDbktKeXRMdnZGT3Q0Vnpiald4ZmQzNjhSaFg1THBycTB2SUJPRkladUxlZkpOd2RVMFpkekpybGFqbVEtUVZZVTdPQUd4Q3ZXVkVFQVJkQlIyNlpobWZkSFBRVjBMdTBxUWZEMEF2dXFkVmR4UW5zdGpGX2R5T0NvaHdaYmJQZVlIMHQxQmdYOEhhNlNGZTZuY0xXOG9aMjhxMUhNYw?oc=5", "source_name": "Reuters", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Today's Analyst Rating Update for Regeneron Pharmaceuticals (REG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOVXdYVXhfZnEzTGdqdXZKNGREU0tyZW1pWmxUOHptRl92OHJ1blZUakhZZ2JQamJyenlHSUxFdTJjUThpcVBnUjhYV3EzQnRiTXNxQ0tsRDZ6SGtiTm16WUdSRTBlUENIcmt1Ym05UVBBR2NqcmRwQ3VQdlY1RkM3VmVnOExFV2xNMDBHbmF4OUQ0dzk0X3FWRUlCaUg0MlhONnU1QkgwU19UWXh0R0kxZGozZVNDRW5ialE?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdHhac3NzT2hjRTJ2VXZOOXhrQXhCR3lEd25wNm9OZXpOekRBTzlfdDBGXzQ1dDdpOUJCUDZKcG5MWUFlYzVDZVFmYVZmcnN3U3hJdVF6aXhneGx6S3hKaTB5ZkFVWjF1WjIxVUc0TTlraFZBLWd3dXVoZVc3V25xRGd4QXJhN08weDBxalN3R20xbWNsQVdzSjVwc0dnTExfdUQzRjkwYjZ4X25ldnhJ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron's immune disorder therapy improves daily functions in trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcXVZS0FBT3NheTNkS29hVm9MSVhqN0lPTVozSGRzcW02UXdqQkN2TUlCWHdmUEpPczQwcEc5d1Y1aU41dFg3eWhDLUpKV2lsLXhITDdLdDZGRGxERUdzeFpBNU1wMVlIVDROQnZ4ZFBxZ3lPMUxEbk44UHF6QmNHMHFJcFRoUHB0NFlBcEhpeEtMOVNuOXhZNzJIWDJ4dFR4bFFoVnlXRU4wZ0JmaFdTMEthdnlNWEczNEhmdUlFNFlCVEFwTzM2enNPZG0tc2t0QlU0?oc=5", "source_name": "Reuters", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxQRHVZZ2c5ZnFWc1c2Um9WTUxIQ05nS0dDUXZvZTE1TktOak5aNk9DSm5MMEFFdHNHS2V0S1ppbTROSk1RT2xfT2hfWnVjYnRoOTRKYmpaY3c2clBrUjNVaGYzNHI1dHNFczUyQ0swbHZLSm9GUHJvWUt6Ri04YnIzZEVFQVN1NGV3Q2w5SWtQTGFuMVRsS0VVRUJCczlQaFpKdnUtSWxJRzdMMTROTURXeExoNF9qYlhvcWtBZ25TS3oxeWRuRnFQbWhtbjd6ajBpUC1FQTdxTWZPVTA3TGQwSzhDcms4ZHdZeEpta2IzeFVmQ2N5bklpczdxZ3l1Tk1BUlE?oc=5", "source_name": "PR Newswire", "published_at": "2025-03-03T08:00:00+00:00", "published_display": "03 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOdU9vV21NTGw4SjN6YmdJS0l2d1pMbXRxdlJRc01ZUkRkaGQyWVQ1OVZpZlowTTNJM0Y5SHhHVXF0cHFJSEFjTW9EQlNiMHFCbUZURFNtcFVuZmtMa1MtcmhkaW5nOWVCQWVRS0F2bkt4c1ZHd2tROThBYloydHNMQjZqLUkzZF9ua0M5OElkelRFQVAwc18xNzNhUThxT3ZnRkoxa2pxUjBYaUFKeWtCcGRFZGY0bFBiSkU0a1NESFNNb2VSMkpTblNrQXVVbWpTemJBOC1KNnJMWmxuQUVjMjVMYWg4TFJscEo1U2VuMmtpM3RBSDNfMlJ1TGJlSHRqdExHbkI3cS1wRkZ2MFAyTTdydnVXVm9LWENCdHNB?oc=5", "source_name": "PR Newswire", "published_at": "2025-01-09T08:00:00+00:00", "published_display": "09 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 77, "total_relevant": 12, "sentiment_summary": {"positive": 2, "negative": 2, "neutral": 8, "score": 52, "total": 12, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 4.2, "count": 7}, {"event": "earnings", "label": "Earnings", "weight": 2.0, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.9, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 579.3, "latest_week": "2026-07-10", "one_week_move": 1.3, "four_week_move": 9.6, "twelve_week_move": -8.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.451794, "market_dynamics_buy_signal": false, "relative_strength": -15.813763, "fair_value_gap": -20.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 21.3942, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.3% over one week, +9.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GuruFocus", "count": 3}, {"label": "Stock Titan", "count": 2}, {"label": "Reuters", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "The Business Journals", "count": 1}, {"label": "Market source", "count": 1}, {"label": "Seeking Alpha", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 12}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 7}, {"label": "Earnings", "count": 3}, {"label": "Macro sensitivity", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "12", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.3% over one week, +9.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion"}], "updated_at": "2026-07-17T19:52:22.081141+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}